An interventional study of Improving Engagement with Vaginal Dilator Therapy after Pelvic Radiation in Pelvic Radiotherapy, Vaginal Stenosis and Pelvic Cancer, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Duke University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Pelvic Neoplasms with a site in United States — 5 open to participants now, 9 under way, 2 of them phase 3. Pelvic Neoplasms · United States.
Among the 28 studies in Pelvic Neoplasms with a site in United States, this one is the 5th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 28th registered.
82 studies on the registry are indexed under Pelvic Neoplasms; 28 are open to participants now.
Browse Pelvic Neoplasms studies →5 of the 28 studies in Pelvic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 6 mo–17 yrs
University of California, San Diego · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Pelvic Neoplasms studies recruiting now, 16 (70%) set no upper age limit and 3 (13%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 47 across 50 interventional studies indexed under Pelvic Neoplasms.
Median enrollment 38 across the 20 interventional studies, 87 across the 8 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 28 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 1 study filed under Pelvic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Pelvic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06915727Phase 3Mayo ClinicAn Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors | 2027-05-01 |
| NCT05134142M.D. Anderson Cancer CenterQuality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Pelvic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing a new program to help women who have had pelvic radiation therapy to use vaginal dilators more regularly. Vaginal dilators are important tools that can help prevent or treat vaginal narrowing (called vaginal stenosis), which can happen after radiation and make medical exams or sexual activity painful or difficult. Even though dilators are recommended, many women don't use them as often as needed.
In Phase I of the study, individual qualitative interviews with patients in the target sample (N=20) and medical providers (N=10) will be used to inform the behavioral program development. In Phase II, the program will be refined through user testing interviews (N=12). In Phase III, 88 participants will be randomly assigned to one of two groups:
The study will look at how often and how long participants use their dilators, and whether the program helps reduce symptoms like pain or emotional distress. Participants will complete surveys at the beginning of the study and again at 3, 6, and 9 months, plus short monthly check-ins.
The goal is to see if the program is helpful and easy to use, and to prepare for a larger study in the future.
This study is testing a new behavioral program to help women who have had pelvic radiation therapy use vaginal dilators more regularly. Vaginal dilators are important tools that help prevent or treat vaginal stenosis-a condition where the vagina becomes shorter or narrower after radiation. This can make medical exams and sexual activity painful or difficult. Although dilators are commonly recommended, many women struggle to use them consistently.
The new program is designed to support women in overcoming common challenges to using dilators, such as pain, emotional distress, and lack of information. It includes strategies from cognitive behavioral therapy and acceptance and commitment therapy, and is based on the Health Belief Model, which helps people understand how their beliefs affect their health behaviors.
In Phase I, individual qualitative interviews with patients in the target sample (N=20) and medical providers (N=10) will be used to inform behavioral program development. It is anticipated that the program will employ strategies from cognitive behavioral therapy and acceptance and commitment therapy. In Phase II, the program will be refined through user testing interviews (N=12). In Phase III, 88 participants will be randomly assigned to one of two groups:
Participants will complete surveys at the beginning of the study and again at 3, 6, and 9 months. They will also complete short monthly check-ins to report how often and how long they use their dilators.
The main goals of the study are to:
This pilot study will help researchers prepare for a larger study in the future and improve support for women recovering from pelvic radiation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A 6-session (45 minutes each) behavioral intervention will be delivered individually and remotely via videoconferencing. The intervention will be designed to improve engagement with vaginal dilator therapy among female cancer survivors who underwent pelvic radiation therapy. The intervention includes coping strategies from cognitive behavioral therapy (e.g., progressive muscle relaxation) and acceptance and commitment therapy (e.g., mindfulness), as well as psychoeducation (e.g., how to use dilators), to enhance engagement with vaginal dilator therapy.
Behavioral: Improving Engagement with Vaginal Dilator Therapy after Pelvic Radiation
Written materials will highlight the purpose of dilator therapy and how to use dilators (including frequency and duration).
The intervention includes coping strategies from cognitive behavioral therapy (e.g., progressive muscle relaxation) and acceptance and commitment therapy (e.g., mindfulness), as well as psychoeducation (e.g., how to use dilators), to enhance engagement with vaginal dilator therapy.
Feasibility, as Measured by Session Completion and Attrition
Feasibility will be determined by 1) greater than or equal to 80% of sessions completed and 2) attrition rate of less than or equal to 20%.
Time frame: 3 months post-baseline
Acceptability, as Measured by the Treatment Acceptability Questionnaire
Acceptability will be determined by average score of 5 or greater on the Treatment Acceptability Questionnaire (TAQ). The TAQ is a six-item measure assessing perceptions of an interventions acceptability, ethics, and effectiveness. Items are rated on a 7-point Likert scale, from "very unacceptable" to "very acceptable".
Time frame: 3 months post-baseline
Change in Dilator Therapy Use
Dilator therapy use will be assessed monthly via text survey by four items used in prior research to assess average frequency of dilator use, average duration of dilator use per dilation, frequency of penetrative sexual activity, and frequency of alternate dilator use over the past month.
Time frame: From baseline to end of study enrollment at 9 months
Completion of cancer screening
Completion of cancer screening/surveillance that involved a pelvic exam will be assessed by asking one item about the frequency of completing recommended pelvic exams for cancer screening/surveillance in the past three months. This will be assessed every 3 months via self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in symptoms, as measured by the Edmonton Symptom Assessment System
The Edmonton Symptom Assessment System is a 10-item self-report scale of 9 common symptoms experienced by cancer patients. There is a 10th item in which patients can write in and rate another specific symptom experienced. Participants are asked to rate individual symptom burden on an 11 point scale (0-10) with higher scores indicating greater symptom burden. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in depressive symptoms, as measured by the PROMIS Depression Short Form
Depressive symptoms will be assessed using the PROMIS Depression Short Form. This is an 8-item measure assessing symptoms of depression experienced over the last week. Participants will be asked to respond to items (e.g., "I felt sad," "I felt helpless") using a five-point scale ranging from "1" (never) to "5" (always). This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in psychological flexibility, as measured by the Acceptance and Action Questionnaire II
The Acceptance and Action Questionnaire II (AAQ-II) is a 7-item measure of psychological flexibility. Participants are asked to rate items on a 7-point scale from "1" (never true) to "7" (always true) and item scores are summed to create a total score between 7 and 49. Higher scores indicate lower psychological flexibility. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in understanding of psychosocial changes as measured by the modified Knowledge Scale
A 14-item modified version of a Knowledge Scale developed by previous researchers will be used to assess understanding of psychosexual changes following pelvic radiation therapy and use and purpose of vaginal dilator therapy and other rehabilitation strategies. Higher summed scores on the knowledge scale indicate greater knowledge. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in self-efficacy, as measured by the modified Generalized Self-Efficacy Scale
The Generalized Self-Efficacy Scale is a 10-item measure of self-efficacy. Respondents are asked to rate individuals items on a 4 point scale from "1" (not at all true) to "4" (exactly true). Items on this measure will be modified to assess self-efficacy with engaging in dilator therapy. Scores will be summed for a total between 10 and 40. Higher summed scores indicate greater self-efficacy to engage in dilator therapy. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in perceived susceptibility to developing vaginal stenosis, benefits and barriers to engaging in dilator therapy, as measured by the modified susceptibility, Benefits and Barriers Scale
The 19-item Revised Susceptibility, Benefits, and Barriers Scale for mammography screening will be modified to assess perceived susceptibility to developing vaginal stenosis, benefits to engaging in dilator therapy, and barriers to engaging in dilator therapy. Items are rated on a 5-point Likert-type scale from "1" (strongly agree) to "5" (strongly disagree). Higher subscale scores indicate a lower degree of perceived susceptibility, benefits, and barriers, respectively. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in cues that prompt health-promoting behaviors, as measured by the modified Cues to Health Action Questionnaire
The Cues to Health Action Questionnaire is a 32-item measure assessing cues that prompt health-promoting behaviors. The specific target action that will be emphasized in measure instructions is engaging in dilator therapy. Respondents will be asked to rank order specific cues to action for engaging dilator therapy. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in sexual feelings and responses, as measured by the Female Sexual Function Index
The Female Sexual Function Index (FSFI) is a 19-item measure assessing sexual feelings and responses over the past 4 weeks. Participants are asked to rate individual items on a 5 or 6 point Likert-type scales, ranging from "0" or "1" to "5", with higher total score indicating greater sexual functioning. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Change in anxiety symptoms, as measured by the PROMIS Anxiety Short-Form
The PROMIS Anxiety Short Form will be used to assess anxiety symptoms. This is an 7-item measure assessing symptoms of anxiety experienced over the last week. Participants will be asked to respond to items using a five-point scale ranging from "1" (never) to "5" (always). Responses will be summed for a total score between 7 and 35, with higher scores indicating higher levels of anxiety symptoms. This will be assessed every 3 months by self-report.
Time frame: From baseline to end of study enrollment at 9 months
Plan to share: Yes — It is our intention to make all data generated from this proposal freely available after it is de-identified. Respondent identifiers will not be shared. All other scientific data (scale composites) will be both preserved and shared. The following data will be preserved and shared: qualitative data, patient-reported data from study assessments, and sociodemographic and medical data collected via patient report and health record. Researchers will make every effort to provide raw data in a non-proprietary format wherever possible to enhance reproducibility.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Data will be shared either at the time of publication or at the end of the performance period, whichever comes first. All data deposited with the Duke Research Data Repository will be retained for a minimum of 25 years according to their stated Retention Policy.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for May 2030, 50 months after the start.
Of 23 interventional studies with no phase under Pelvic Neoplasms, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.